Molecular Weight(MW): 493.94
Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
|Description||Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.|
Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria. 
|In vivo||Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo).  Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. |
|In vitro||Water||1 mg/mL warmed (2.02 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03291158||Not yet recruiting||Drug: Minocycline||Normal Healthy Volunteers||Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|Universitätsklinikum Köln|Innovative Medicines Initiative||April 2018||Phase 1|
|NCT03160040||Completed||Drug: Minocycline IV||Gram-Negative Bacterial Infections||Rempex (a wholly owned subsidiary of Melinta Therapeutics Inc.)|Melinta Therapeutics Inc.||October 11 2017||--|
|NCT02808052||Terminated||Drug: Minocin (minocycline) for Injection||Renal Insufficiency Acute|Renal Insufficiency Chronic|Healthy Subjects||Rempex (a wholly owned subsidiary of Melinta Therapeutics Inc.)|Universitätsklinikum Köln|Innovative Medicines Initiative|Melinta Therapeutics Inc.||May 29 2017||Phase 1|
|NCT02802631||Completed||Drug: Minocin (minocycline) for Injection|Other: Placebo||Normal Healthy Volunteers||Rempex (a wholly owned subsidiary of Melinta Therapeutics Inc.)|Universitätsklinikum Köln|Innovative Medicines Initiative|Melinta Therapeutics Inc.||April 20 2017||Phase 1|
|NCT03117530||Recruiting||Drug: Minocycline||Autism Spectrum Disorder||University of California Los Angeles||April 11 2017||Phase 1|
|NCT02695446||Completed||Drug: Minocycline||Acne||BioPharmX Inc.||March 2016||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.